Fig. 5: BinJ/JEV_NSW/22-prME provides partial cross protection against MVEV_TC123130 in Ifnar^-/- mice.

a Timeline of BinJ/JEV_NSW/22-prME vaccinations, MVEV challenge, and sample/data collections. b Serum end point neutralizing antibody titers against either JEV_NSW/22 or MVEV after two vaccinations. Limit of quantification 1 in 5. (Statistics by Wilcoxon matched-pairs signed rank tests). c Mean percent mouse body weight change relative to day 0 for each mouse (n = 6 per group). Statistics by repeated measure ANOVA for 1 to 4 dpi (p = 0.008). d Clinical disease scores for posture (circles), activity (crosses) and fur ruffling were monitored in Ifnar^-/- mice. n = 6 PBS injected, n = 12 BinJ/JEV_NSW/22-prME vaccinated until 4 dpi, n = 6 BinJ/JEV_NSW/22-prME vaccinated until humane endpoint reached. † Ethically defined end point reached for euthanasia. Statistics by Kolmogorov-Smirnov exact tests (n = 6 PBS vaccinated, n = 12 BinJ/JEV_NSW/22-prME vaccinated on 4 dpi), p < 0.05 for each disease parameter. e % survival; time until mice reached ethically defined end points for euthanasia, n = 6 per group. Significance by log rank statistic. f Post-challenge viremia in Ifnar^-/- mice determined by TCID₅₀ assays. Viremia for individual mice at each time point. Limit of detection was 2 log₁₀TCID₅₀/ml. ND not detected. In the BinJ/JEV_NSW/22-prME vaccinated group no viremia was detected on any day in 4/12 mice (blue square with red boarder). Statistics by Kolmogorov-Smirnov exact test on 2 dpi (n = 6 PBS injected, n = 12 BinJ/JEV_NSW/22-prME vaccinated).